FindTrial
Sign In

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518013-25-00
Enrollment
17
Registered
2026-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

Absolute change from baseline in forced vital capacity (mL) at Week 24.

Detailed description

Absolute change from baseline in FVC (mL) at Week 52., Relative change from baseline in FVC (mL) at Week 24., Relative change from baseline in FVC (mL) at Week 52., Absolute and relative change from Baseline in FVC % predicted at Week 24., Absolute and relative change from Baseline in FVC % predicted at Week 52., Time to first ≥ 10% absolute decline in FVC% predicted., Time to first ≥ 5% absolute decline in FVC% predicted.

Interventions

DRUGPlacebo for ABBV-142

Sponsors

AbbVie Deutschland GmbH & Co. KG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Absolute change from baseline in forced vital capacity (mL) at Week 24.—

Secondary

MeasureTime frame
Absolute change from baseline in FVC (mL) at Week 52., Relative change from baseline in FVC (mL) at Week 24., Relative change from baseline in FVC (mL) at Week 52., Absolute and relative change from Baseline in FVC % predicted at Week 24., Absolute and relative change from Baseline in FVC % predicted at Week 52., Time to first ≥ 10% absolute decline in FVC% predicted., Time to first ≥ 5% absolute decline in FVC% predicted.—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 12, 2026